Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in the Japanese population

(2020) Kazuhiko Nakagawa et al.   Future Oncology

Network meta-analyses for EGFR mutation-positive non-small-cell lung cancer: systematic review and overview of methods and shortcomings

(2020) Carl Samuelsen et al.   Journal of Comparative Effectiveness Research

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

(2019) Martin Schuler et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

(2019) Haruhiro Saito et al.   LANCET ONCOLOGY

Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study

(2019) Yi-Long Wu et al.   LUNG CANCER

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials

(2019) Martin Schuler et al.   LUNG CANCER

Combination of metformin and gefitinib as first-line therapy for non-diabetic advanced NSCLC patients with EGFR mutations: A randomized, double-blind phase 2 trial

(2019) Li Li et al.   CLINICAL CANCER RESEARCH

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer

(2019) Vanita Noronha et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis

(2019) Carlo Buonerba et al.   Cancers

LBA19Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations

(2019) T S K Mok et al.   ANNALS OF ONCOLOGY

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

(2019) Yukio Hosomi et al.   JOURNAL OF CLINICAL ONCOLOGY

P2.14-02 Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial)

(2019) C. Genova et al.   Journal of Thoracic Oncology

First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis

(2019) Hongwei Zhang et al.   PLoS One

Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis

(2019) Yi Zhao et al.   BMJ-British Medical Journal

A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis

(2019) James Chih-Hsin Yang et al.   Journal of Thoracic Oncology

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

(2019) Giorgio Scagliotti et al.   Journal of Thoracic Oncology

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Kazuhiko Nakagawa et al.   LANCET ONCOLOGY

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

(2018) Yi-Long Wu et al.   Clinical Lung Cancer

139PD Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)

(2018) N. Leighl et al.   Journal of Thoracic Oncology

128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes

(2018) D. Planchard et al.   Journal of Thoracic Oncology

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer

(2018) Tamkin Ahmadzada et al.   Journal of Clinical Medicine

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Thanyanan Reungwetwattana et al.   JOURNAL OF CLINICAL ONCOLOGY

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset

(2018) Byoung Chul Cho et al.   Journal of Thoracic Oncology

First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials

(2017) M. Schuler et al.   EUROPEAN JOURNAL OF CANCER

Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial

(2017) Baohui Han et al.   INTERNATIONAL JOURNAL OF CANCER

P3.01-072 Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR+ NSCLC in Japanese Patients (ARCHER 1050)

(2017) K. Nakagawa et al.   Journal of Thoracic Oncology

OA 05.02 Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis

(2017) J. Gray et al.   Journal of Thoracic Oncology

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

(2017) Yi-Long Wu et al.   LANCET ONCOLOGY

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

(2016) Ying Cheng et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non–Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study

(2016) James Chih-Hsin Yang et al.   Journal of Thoracic Oncology

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma

(2016) Tony Shu Kam Mok et al.   Journal of Thoracic Oncology

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

(2016) Martin Schuler et al.   Journal of Thoracic Oncology

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

(2016) Keunchil Park et al.   LANCET ONCOLOGY

Asthma control and severe exacerbations in patients with moderate or severe asthma in Jilin Province, China: a multicenter cross-sectional survey

(2016) Bing-di Yan et al.   BMC Pulmonary Medicine

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

(2015) Brian Hutton et al.   ANNALS OF INTERNAL MEDICINE

109PD * OVERALL SURVIVAL (OS) WITH AFATINIB (A) VS CHEMOTHERAPY (CT) IN PATIENTS (PTS) WITH NSCLC HARBOURING EGFR MUTATIONS (MUT): SUBGROUP ANALYSES BY RACE IN LUX-LUNG 3 (LL3) AND LUX-LUNG 6 (LL6)

(2015) M. Schuler et al.   ANNALS OF ONCOLOGY

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902

(2015) S. Sugawara et al.   ANNALS OF ONCOLOGY

First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

(2015) Y.-L. Wu et al.   ANNALS OF ONCOLOGY

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activatingEGFRmutations: Subgroup analysis of LUX-Lung 3

(2015) Terufumi Kato et al.   CANCER SCIENCE

Erlotinib and bevacizumabversuscisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer

(2015) Michael Thomas et al.   EUROPEAN RESPIRATORY JOURNAL

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer

(2015) Sarayut L Geater et al.   Journal of Thoracic Oncology

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer

(2014) Hui Yu et al.   CANCER BIOLOGY & THERAPY

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial

(2014) James Chih-Hsin Yang et al.   EUROPEAN JOURNAL OF CANCER

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

(2014) Takashi Seto et al.   LANCET ONCOLOGY

Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers

(2013) Jeroen P Jansen et al.   BMC Medicine

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma WithEGFRMutations

(2013) James Chih-Hsin Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Evidence Synthesis for Decision Making 4

(2013) Sofia Dias et al.   MEDICAL DECISION MAKING

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

(2012) Pasi A. Jänne et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

(2012) Cesare Gridelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer

(2012) Massimo Di Maio et al.   Journal of Thoracic Oncology

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

(2012) Julian R. Molina et al.   MAYO CLINIC PROCEEDINGS

A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer

(2011) Fred R. Hirsch et al.   JOURNAL OF CLINICAL ONCOLOGY

Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial

(2010) Beth S Woods et al.   BMC Medical Research Methodology

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE